Publish in this journal
Journal Information
Vol. 72. Issue 11.
Pages 983 (November 2019)
Letter to the Editor
DOI: 10.1016/j.rec.2019.01.003
Full text access
Galectin-3, Carbohydrate Antigen 125 and Transcatheter Aortic Valve Implantation
Galectina 3, antígeno carbohidrato 125 e implante percutáneo de prótesis aórtica
Beuy Jooba,
Corresponding author

Corresponding author:
, Viroj Wiwanitkitb
a Medical Center Unit, Medical Academic Center, Bangkok, Thailand
b Department of Biological Science, Joseph Ayobabalola University, Ikeji-Arakeji, Nigeria
Related content
Rev Esp Cardiol. 2019;72:907-1510.1016/j.rec.2018.09.006
Tobias Rheude, Costanza Pellegrini, Julio Núñez, Michael Joner, Teresa Trenkwalder, N. Patrick Mayr, Stefan Holdenrieder, Vicent Bodi, Wolfgang Koenig, Albert M. Kasel, Heribert Schunkert, Adnan Kastrati, Christian Hengstenberg, Oliver Husser
This item has received
(Daily data update)
Article information
Full Text
Download PDF
Full Text
To the Editor,

We read the publication Differential Prognostic Value of Galectin-3 According to Carbohydrate Antigen 125 (CA125) Levels in Transcatheter Aortic Valve Implantation with a great interest.1 Rheude et al. concluded that “In patients undergoing TAVI, Gal-3 predicts adverse clinical outcomes, but only in the presence of elevated CA125 values.”1 In fact, galectin-3 is a new biomarker that has been reported to be useful in diagnosing cardiac disorders as well as other medical problems (such as cancer and endocrine disorders).2,3 Several pathological conditions can result in abnormal galectin-3 levels. In the present report, it is not possible to rule out any other concomitant medical disorders. The interesting question concerns the source of elevated carbohydrate antigen 125 levels in some cases. Carbohydrate antigen 125 might increase in some patients with heart failure4 but it can also increase in several conditions in women, such as ovarian tumors and endometriosis. To enhance the diagnostic capability of carbohydrate antigen 125 in cardiac problems, a recent report showed that coinvestigating for copeptin level is useful.5

T. Rheude, C. Pellegrini, J. Núñez, et al.
Differential Prognostic Value of Galectin-3 According to Carbohydrate Antigen 125 Levels in Transcatheter Aortic Valve Implantation.
Rev Esp Cardiol., 72 (2019), pp. 907-915
M. Gudowska, L. Chrostek.
Diagnostic role of galectin-3.
Pol Merkur Lekarski., 37 (2014), pp. 348-352
R. Dong, M. Zhang, Q. Hu, et al.
Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review).
Int J Mol Med., 41 (2018), pp. 599-614
P. Llàcer, A. Bayés-Genís, J. Núñez.
Carbohydrate antigen 125 in heart failure.
New era in the monitoring and control of treatment. Med Clin (Barc)., (2018),
Y. Ding, Q. Wang, Y. Yang, L. Wang.
Diagnostic value of copeptin and cancer antigen 125 in acute heart failure patients with atrial fibrillation and their correlations with short-term cardiovascular events.
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue., 30 (2018), pp. 1024-1028
Copyright © 2019. Sociedad Española de Cardiología
Revista Española de Cardiología (English Edition)

Subscribe to our newsletter

Article options
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.